Durham, N.C., Nov. 10, 2016 – The Drug Supply Chain Security Act, part of the Drug Quality and Security Act signed by President Obama in 2013, demands error-free serialization and tracking of pharmaceutical products throughout the entire supply chain. In November 2017, pharmaceutical manufacturers will be expected to comply with item-serialization requirements, with requirements for repackagers to follow in 2018.
With extensive expertise in factory intelligence and secure item tracking, Bell and Howell will be hosting a complimentary Southeast Traceability & Serialization Forum on November 17 to help pharmaceutical companies learn from their peers and other experts about how to refine their path to compliance with the DSCSA. The event will be held at the Bell and Howell facility located at 3791 South Alston Avenue in Durham, North Carolina.
Attendees will be able to spend time with industry experts as they deliver a comprehensive review of the DSCSA; engage in discussion on the supply chain’s evolving demands and threats to existing serialization-line solutions; and expand their network of peers who can help work through the challenges of compliance.
“Rapid changes in the global regulatory environment, including the enactment of the Drug Supply Chain Security Act here in the USA, are driving the need for serialization in the pharmaceutical supply chain,” said Roger Saumure, president of Excellis Health Solutions. “Events like the Southeast Traceability & Serialization Forum can help educate and empower compliance and logistics professionals whose companies are affected by these regulations.”
Bell and Howell has assembled an impressive lineup of thought leaders and industry experts, including Kevan MacKenzie, director of serialization technology at McKesson; Randy Feldman, chief solution architect at Excellis Health Solutions; and Andy Meyer, serialization lead and senior systems analyst at North Carolina Mutual Wholesale Drug Company.
The agenda for the Southeast Traceability & Serialization Forum includes the following activities:
“We are thrilled to be able to bring the regional pharmaceutical community together to discuss this important topic,” said Larry Blue, chief operating officer at Bell and Howell. “The impact the DSCSA is having on the industry’s supply chain cannot be overstated. But we have put together an information-packed day with industry experts and some amazing demonstrations to help guide us.”
To learn more about Bell and Howell, visit bellhowell.net, call 1-800-220-3030, or follow the company on LinkedIn and Twitter.
Bell and Howell delivers innovative service and technology solutions that enrich customer communications and fulfillment for the world’s largest finance, industry and public sector enterprises. The company helps its customers streamline high-volume, high-integrity production of customer communications and product fulfillment, track delivery throughout the supply chain, maximize postal discounts, and monetize every customer touchpoint. Our service organization is among the most sophisticated in the world of production workflow, automation and industrial mechatronics. Headquartered in Research Triangle Park, N.C., with offices around the world, Bell and Howell is the trusted partner to thousands of organizations globally. For additional information, visit BellHowell.net.